Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Ribera

Showing results (441-450 of 473) with videos related to

Pageof 48
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 30, 2015
Changes in the influence of lymphoma- and HIV-specific factors on outcomes in AIDS-related non-Hodgkin lymphomaS K Barta, M S Samuel, X Xue, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1996
Feasibility and results of bone marrow transplantation after remission induction and intensification chemotherapy in de novo acute myeloid leukemia. Catalan Group for Bone Marrow TransplantationJ Sierra, S Brunet, A Grañena, et al.
Haematologica|April 22, 2006
Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) StudyJavier de la Rubia, Joan Bladé, Juan-José Lahuerta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 30, 2008
Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapyGema Mateo, M Angeles Montalbán, Maria-Belén Vidriales, et al.
Leukemia Research|August 13, 2005
Adverse prognostic impact of CD36 and CD2 expression in adult de novo acute myeloid leukemia patientsG Perea, A Domingo, N Villamor, et al.
Leukemia|June 7, 2017
Long-term outcome of older patients with newly diagnosed de novo acute promyelocytic leukemia treated with ATRA plus anthracycline-based therapyD Martínez-Cuadrón, P Montesinos, E Vellenga, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 5, 2024
Human immunodeficiency virus-associated lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upK Hübel, M Bower, I Aurer, et al.
Bone Marrow Transplantation|January 9, 2021
Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides and Sézary syndrome. An updated experience of the Lymphoma Working Party of the European Society for Blood and Marrow TransplantationE Domingo-Domenech, R F Duarte, A Boumedil, et al.
Actas Dermo-Sifiliograficas|May 24, 2014
Evidence-based guidelines of the spanish psoriasis group on the use of biologic therapy in patients with psoriasis in difficult-to-treat sites (nails, scalp, palms, and soles)M Sánchez-Regaña, M J Aldunce Soto, I Belinchón Romero, et al.
Haematologica|August 28, 2001
Additional cytogenetic changes do not influence the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with an ATRA plus anthracyclin based protocol. A report of the Spanish group PETHEMAJ M Hernández, G Martín, N C Gutiérrez, et al.
Pageof 48

Showing results (441-450 of 473) with videos related to

Sort By:
Pageof 48
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 30, 2015
Changes in the influence of lymphoma- and HIV-specific factors on outcomes in AIDS-related non-Hodgkin lymphomaS K Barta, M S Samuel, X Xue, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1996
Feasibility and results of bone marrow transplantation after remission induction and intensification chemotherapy in de novo acute myeloid leukemia. Catalan Group for Bone Marrow TransplantationJ Sierra, S Brunet, A Grañena, et al.
Haematologica|April 22, 2006
Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) StudyJavier de la Rubia, Joan Bladé, Juan-José Lahuerta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 30, 2008
Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapyGema Mateo, M Angeles Montalbán, Maria-Belén Vidriales, et al.
Leukemia Research|August 13, 2005
Adverse prognostic impact of CD36 and CD2 expression in adult de novo acute myeloid leukemia patientsG Perea, A Domingo, N Villamor, et al.
Leukemia|June 7, 2017
Long-term outcome of older patients with newly diagnosed de novo acute promyelocytic leukemia treated with ATRA plus anthracycline-based therapyD Martínez-Cuadrón, P Montesinos, E Vellenga, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 5, 2024
Human immunodeficiency virus-associated lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upK Hübel, M Bower, I Aurer, et al.
Bone Marrow Transplantation|January 9, 2021
Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides and Sézary syndrome. An updated experience of the Lymphoma Working Party of the European Society for Blood and Marrow TransplantationE Domingo-Domenech, R F Duarte, A Boumedil, et al.
Actas Dermo-Sifiliograficas|May 24, 2014
Evidence-based guidelines of the spanish psoriasis group on the use of biologic therapy in patients with psoriasis in difficult-to-treat sites (nails, scalp, palms, and soles)M Sánchez-Regaña, M J Aldunce Soto, I Belinchón Romero, et al.
Haematologica|August 28, 2001
Additional cytogenetic changes do not influence the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with an ATRA plus anthracyclin based protocol. A report of the Spanish group PETHEMAJ M Hernández, G Martín, N C Gutiérrez, et al.
Pageof 48